Stay updated on Soticlestat in Rare Epilepsies Clinical Trial
Sign up to get notified when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.
Latest updates to the Soticlestat in Rare Epilepsies Clinical Trial page
- Check2 days agoChange DetectedThe ENDYMION 1 study (NCT03635073) was terminated due to negative results from related phase 3 studies, and supplementary data were deemed unnecessary. The record now reflects the termination and includes posted results and QC date updates in 2026.SummaryDifference0.1%
- Check9 days agoChange DetectedAdded 'Severe myoclonic epilepsy in infancy' to the Conditions section and removed 'Dravet syndrome'.SummaryDifference0.0%
- Check16 days agoChange DetectedAdded a Results Posted entry with detailed long-term safety and outcome data (ECG, vital signs, labs, seizures, and behavioral measures) and related documentation; removed the prior Results Submitted content and associated metrics.SummaryDifference4%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%
- Check38 days agoChange DetectedThe study status is updated to Terminated, with notes indicating closure due to external results; the record now reflects that this study is no longer active.SummaryDifference0.1%
- Check45 days agoChange DetectedStudy status updated to Terminated with a justification that supplementary data is no longer necessary following negative results from related trials; the study is now closed.SummaryDifference0.0%
Stay in the know with updates to Soticlestat in Rare Epilepsies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.